Valuation
- Market cap
- 4,634,000
- Revenue TTM
- $0
- Net income TTM
- $-10,210,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 4.80
Trading
- Volume
- 16,217
- Avg volume
- 268,304
- Day's range
- $3.30 – $3.55
- Shares out
- 1,343,000
- Stochastic %K
- 1%
- Beta
- 4.97
- Analysts
- Strong Buy
- Price target
- —
Company profile
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 213 273 5453
- Website
- https://liminatuspharma.com
- Address
- 12611 Hiddencreek Way, Unit C, Cerritos, United States
Latest news
No headlines yet.
